Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndrome. NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndrome.

Cancer Invest. 1989;7(3):225-9. Unique Identifier : AIDSLINE MED/90002301
Chachoua A; Green MD; Valentine F; Muggia FM; Rita and Stanley H. Kaplan Cancer Center, New York University; School of Medicine, New York 10016.

Abstract: Fifteen patients with acquired immune deficiency syndrome (AIDS) and opportunistic infection, were randomized to receive treatment with either thymostimulin (TP-1) at 1 mg/kg for 14 days then weekly for 12 weeks or placebo. The objectives of this study were to evaluate the toxicity of TP-1 in this patient population and to make observations on clinical response as measured by time to second opportunistic infection (OI) and changes in laboratory parameters of immune function. The study demonstrates that TP-1 can be administered safely. There were no differences, however, in time to second OI or overall survival between patient groups. In addition, no change in the immune function could be detected in patients receiving thymostimulin.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Adult Biological Response Modifiers/THERAPEUTIC USE Double-Blind Method Drug Evaluation Human Immunotherapy Lymphocyte Transformation Opportunistic Infections/*THERAPY Pneumonia, Pneumocystis carinii/THERAPY Support, Non-U.S. Gov't Thymus Extracts/ADVERSE EFFECTS/*THERAPEUTIC USE CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIALKWDacquiredimmunodeficiencysyndrome/immunology/KWDtherapyadultbiologicalresponsemodifiers/therapeuticusedouble-blindmethoddrugevaluationhumanimmunotherapylymphocytetransformationopportunisticinfections/KWDtherapypneumonia,pneumocystiscarinii/therapysupport,non-uKWDsKWDgov'tthymusextracts/adverseeffects/KWDtherapeuticuseclinicaltrialjournalarticlerandomizedcontrolledtrial
900130
M9010503

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .